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Abstract: About one third of patients with schizophrenia respond unsatisfactorily to antip-
sychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in 
these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. 
In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with 
different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this 
review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy 
or combination therapy for patients with treatment-resistant schizophrenia. The evidence for 
aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than 
clozapine is scant, and no recommendation can be made on the basis of the currently available 
data. More effort has been made in describing combinations of aripiprazole and clozapine. Most 
of the open-label and case studies as well as case reports have shown positive effects of this 
combination on overall psychopathology and to some extent on negative symptoms. Several 
reports describe the possibility of dose reduction for clozapine in combination with aripipra-
zole, a strategy that might help so-called “treatment-intolerant” patients. The findings of four 
randomized controlled trials with respect to changes in psychopathology seem less conclusive. 
The most commonly found beneficial effects are better metabolic outcomes and indicators of 
the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are 
repeatedly reported. Further, none of the studies report longer-term outcomes. In the absence of 
alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole 
with clozapine in clozapine-resistant or clozapine-intolerant patients seems to be worthy of 
further investigation from the pharmacological and clinical points of view.
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Treatment-resistant schizophrenia  
and its management challenges
Schizophrenia is a severe psychiatric disorder with one-year incidence rates of about 
15/100,000 persons that affects about 26.3 million people worldwide,1 making schizo-
phrenia and schizophrenia-related disorders frequently chronic illnesses. Schizophrenia 
is among the 20 leading causes of disability, and ranks even higher in low-income 
countries and in men.1 Since the serendipitous discovery of chlorpromazine in the 
1950s, antipsychotic drugs have been effective treatments for psychotic symptoms 
and have reduced hospitalization rates.2 The majority of patients with schizophrenia 
respond adequately to treatment with antipsychotics.3 However, more than a third of 
patients do not respond to conventional first-choice treatments3 and are deemed to be 
“treatment-resistant”.
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There have been repeated debates on the definition of 
treatment resistance and treatment response,4 and trials 
have inconsistently used one or the other definition. A well 
known definition of treatment resistance is the one based 
on the criteria put forward by Kane et al, ie, at least three 
prior antipsychotic treatments within the previous 5 years at 
chlorpromazine dosages $ 1000 mg/day for at least 6 weeks 
without sufficient reduction of positive symptoms or lack of 
a period of good functioning in the last 5 years; additional 
requirements are moderately severe symptoms as well as 
lack of improvement with haloperidol # 60 mg/day for 
at least 6 weeks.5 In the available research trials, patients 
are usually deemed treatment-resistant when 1–3 trials of 
antipsychotic drugs, each lasting for more than 4–6 weeks 
at adequate doses, ie, chlorpromazine-equivalent doses of 
400–1000 mg/day, have failed to reduce positive symp-
toms sufficiently.4 For clinical decision-making in real-life 
settings,6 several guidelines propose treatment resistance 
after 2–3 trials, including at least one atypical antipsychotic 
in adequate dosages for at least 4–6 or 6–8 weeks7,8 without 
satisfactory clinical improvement, thus taking into account 
a multidimensional approach of clinical symptoms, psycho-
social functioning, and well-being. After that, treatment with 
clozapine should be considered.7,8
Indeed clozapine, the first atypical antipsychotics intro-
duced in the early 1970s, is still the gold standard for patients 
with schizophrenia whose symptoms do not sufficiently 
improve on antipsychotic treatment, and its superior efficacy 
in treatment resistance is well documented.2,9,10 However, 
about 40%–70% of patients with treatment-refractory schizo-
phrenia do not respond fully, even to clozapine.11 Further, its 
general use, especially at effective dosages, can be limited 
by a series of relevant to the point of life-threatening side 
effects, such as sedation, sialorrhea, metabolic disturbances, 
weight gain, emerging obsessive-compulsive symptoms, 
agranulocytosis, cardiomyopathy, and delirium or seizures,12 
thereby introducing a further subgroup of seemingly 
treatment-resistant patients, ie, those who are treatment-
intolerant. Other important factors that might be related to 
insufficient response are comorbid substance misuse, inad-
equate duration of treatment, and inadequate dosage.13 Also, 
with   discontinuation rates for antipsychotic medications of 
74% after 18 months in the CATIE (Clinical Antipsychotic 
Trials of Intervention Effectiveness) study14 and up to 90% 
after one year in a later study,15 nonadherence or dimin-
ished   treatment adherence, reflecting patient satisfaction, 
  acceptability, quality of life, and insight, have to be taken into 
account as one further reason for insufficient responses.16–18 
Potential nonfatal side effects associated with clozapine such 
as hypersalivation, weight gain, and sedation may even foster 
lower adherence rates, as well as increased issues of (self-)
stigmatization, low self-esteem, and relapse.
A recently published overview of systematic reviews eval-
uated the effectiveness and safety of different antipsychotics 
in treatment-resistant schizophrenia,19 and concluded that the 
main advantage of atypical antipsychotics lies in their more 
favorable safety profile, which might also increase adher-
ence to treatment. In the same vein, combination therapy of 
antipsychotics might also be useful, to the point of superiority 
of antipsychotic polypharmacy suggested for specific patient 
groups.20 Indeed, a meta-analysis by Taylor et al conveyed 
evidence for a modest effect of augmenting clozapine with a 
second antipsychotic without significant losses in tolerability 
in the short term. However, important considerations, such 
as long-term effects and the choice of antipsychotics, are 
still uncertain,21 and clear evidence favoring one adjunctive 
strategy over another are still scarce.22
In the search for other strategies to treat treatment-
resistant schizophrenia, drugs with unique pharmacological 
profiles such as aripiprazole raise new hopes, but are they 
valid? The aim of this review was to evaluate aripiprazole, its 
advantages and pitfalls as a potential strategy in monotherapy 
or combination therapy for patients with treatment-resistant 
schizophrenia.
Rationale for aripiprazole  
in treatment-resistant schizophrenia
Pharmacology
Among the currently available antipsychotic drugs, aripipra-
zole shows a unique pharmacological profile. Via its partial 
agonism, it binds with high affinity to dopaminergic D2 and 
D3 receptors and serotonergic 5-HT1A receptors, and acts as 
an antagonist at 5-HT2A and 5-HT2C receptors.23,24 Unlike 
other antipsychotic drugs, the affinity of aripiprazole for 
muscarinergic and histaminergic H1 receptors is low. Strong 
dopamine D2 blockade and activity at the serotonin receptors 
as well as at postsynaptic D2 receptors might be responsible 
for its efficacy in reducing positive and somewhat negative 
symptoms, respectively.25
Early clinical trials of aripiprazole in schizophrenic 
patients have shown antipsychotic efficacy comparable with 
that of risperidone or haloperidol.26–30 In a recent Cochrane 
review of 2595 patients included in nine randomized con-
trolled trials (RCT) on the efficacy of aripiprazole versus 
placebo in schizophrenia and schizophrenia-like psychoses, 
a significant benefit of aripiprazole was found for short-term 
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and medium-term relapse rates and compliance with the 
protocol. However, insufficient data were available to assess 
relevant outcome variables, such as death, general, cognitive 
and economic outcomes, engagement with the service, and 
patient satisfaction.31 Reviewing four trials including 1404 
patients for the Cochrane database, Komossa et al reported 
on the efficacy and tolerability of aripiprazole compared with 
olanzapine and with risperidone.32 Aripiprazole was shown to 
be less effective than olanzapine but equal to risperidone in 
improving general mental state. With respect to side effects, 
patients on aripiprazole showed fewer side effects, such as 
cholesterol increase and weight gain, sedation and prolactin-
associated side effects compared with olanzapine, and less 
dystonia, fewer QTc interval abnormalities, and a smaller 
prolactin and cholesterol increase compared with risperidone. 
On the other hand, more patients on aripiprazole experienced 
tremor than those on risperidone.32 However, with patients 
leaving the trials early at a rate of 38.5%, the validity of these 
findings could be questioned. In another systematic review, 78 
RCT with atypical antipsychotics including 13,558 patients 
were evaluated, and olanzapine was found to have superior 
efficacy compared with aripiprazole, quetiapine, risperidone, 
and ziprasidone, while risperidone was found to be superior 
to quetiapine and ziprasidone, and clozapine at dosages . 
400 mg/day were more efficacious than risperidone.33 Com-
parison with typical antipsychotics confers a clear advantage 
for aripiprazole with respect to side effects, with comparable 
efficacy for symptomatic improvement in a further review of 
nine RCT including 3122 patients with schizophrenia.34
Advantages of aripiprazole
A lower propensity for extrapyramidal side effects, sedation, 
weight gain, hyperprolactinemia, and other potential side 
effects can be deduced from the pharmacological profile of 
aripiprazole. Treatment of schizophrenia with aripiprazole 
has been shown to induce fewer side effects compared with 
treatment using first-generation antipsychotics34 as well as 
with olanzapine and risperidone with regard to metabolic, 
prolactin-related, and dystonic side effects or QTc prolonga-
tion.32,35 Conversely, switching treatment to aripiprazole could 
reduce weight gain under olanzapine or clozapine according 
to a recent meta-analysis including 784 patients. However, 
mean weight reduction was modest (−2.55 ± 1.5 kg).36 Other 
groups have found similar tendencies towards weight gain for 
aripiprazole and other antipsychotics, such as perphenazine 
in treatment-resistant patients37 and risperidone in patients 
termed “chronic” or suffering from their first schizophrenic 
episode.38 A critical review concludes that the potential 
advantages of aripiprazole with respect to weight changes are 
still conflicting and need confirmation in a larger sample.39 
In a clinical practice analysis, aripiprazole, quetiapine, and 
amisulpride did not carry an increased risk of diabetes mel-
litus.40 In a head-to-head meta-analysis of the metabolic 
side effects of second-generation antipsychotics in RCT, 
aripiprazole (like amisulpride) showed intermediate or 
low elevations in weight, cholesterol, and glucose levels in 
comparison with other second-generation antipsychotics.41 
A meta-analysis comparing amisulpride, aripiprazole, olan-
zapine, quetiapine, risperidone, sertindole, and ziprasidone 
found aripiprazole to be a second-generation antipsychotic 
with a statistically significant lower risk and lower mean 
change in QTc interval.42
Further to these effects, adding aripiprazole, a partial 
dopamine agonist, to a strong dopamine agonistic antip-
sychotic such as haloperidol has been shown to reverse 
hyperprolactinemia and associated menstrual disturbances 
in a highly significant number of patients compared with 
placebo.43 The industry-sponsored STAR (Schizophrenia 
Trial of Aripiprazole) study revealed improvement in sexual 
dysfunction with aripiprazole, in addition to decreases in 
prolactin levels.44
The relatively fewer metabolic side effects might be one 
of the reasons explaining the recent finding by Azekawa et al 
of a significantly longer time to discontinuation of treatment 
compared with olanzapine, risperidone, and blonanserin in 
patients with schizophrenia and schizoaffective disorder.45 
This is of great relevance because nonadherence and early 
discontinuation of treatment can be in a causal relation-
ship with supposed treatment resistance. However, within 
12 months, no significant difference in discontinuation rates 
between aripiprazole, chlorpromazine, clozapine, sulpiride, 
risperidone, olanzapine, and quetiapine was demonstrated 
in a large Chinese multicenter study, all percentages being 
around 40%.17
Studies have shown beneficial effects of aripiprazole 
on negative symptoms, but without superiority over other 
second-generation antipsychotics;37,46 albeit a lack of an 
improvement in negative symptoms in general, in a small 
pilot study, aripiprazole-treated patients with schizophrenia 
significantly improved on anhedonia and subjective well 
being scores compared with those on risperidone.47
It is well known that obsessive-compulsive symptoms in 
schizophrenia can be worsened by atypical antipsychotics like 
olanzapine or clozapine.48 Recently, aripiprazole has been 
shown to improve these symptoms, but sample sizes were 
very small or of a case report nature.49–54 Nevertheless, newly 
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emergent obsessive-compulsive symptoms during treatment 
with aripiprazole have also been reported in two cases.55
Problems with aripiprazole
Notwithstanding the abovementioned safety benefits of 
aripiprazole, this antipsychotic may also pose new prob-
lems, in addition to those known from other antipsychotics. 
Adverse effects such as nausea, insomnia, and agitation 
have a higher occurrence rate with aripiprazole compared 
with typical antipsychotics and with placebo.31,34 Recently 
published adverse effects at a single case report level are 
rhabdomyolysis56 and transient myopia.57
Extrapyramidal symptoms and akathisia
In early industry-sponsored clinical trials, aripiprazole 
showed slightly more extrapyramidal symptoms and akath-
isia compared with placebo, but less than for haloperidol or 
risperidone.58 Later, there were several reports of general 
extrapyramidal symptoms,59–61 acute dystonic reactions,62–65 
and tardive dyskinesia66 in patients on treatment with 
aripiprazole. On the other hand, in some cases, treatment with 
aripiprazole led to improvements in antipsychotic-induced 
tardive dyskinesia.67,68 A commonly reported side effect of 
treatment with aripiprazole is akathisia. A recent review of 
clinical trials assessing the occurrence of akathisia in patients 
with schizophrenia and schizoaffective disorders reported 
mild to moderate akathisia in 9% of aripiprazole-treated and 
6% of placebo-treated patients, 12.5% of aripiprazole-treated 
versus 24% of haloperidol-treated patients, and 11% of 
aripiprazole-treated versus 6% of olanzapine-treated patients. 
However, discontinuation due to akathisia was low, with 0.3% 
for aripiprazole versus 0% for placebo, 0.9% for aripiprazole 
versus 2.3% for haloperidol, and 1.2% for aripiprazole versus 
0.2% for olanzapine. This analysis did not reveal compromise 
in clinical response due to treatment-emergent akathisia.69 
However, it should be noted that in everyday clinical practice 
it is not always easy to distinguish clearly whether agita-
tion, worsening of psychotic symptoms, and akathisia are 
side effects of medication or inherent in the acute illness. 
A number of management strategies for akathisia occurring 
with second-generation antipsychotics have been reported, 
with different levels of evidence.70,71
Exacerbation of psychosis  
and induction of manic episodes
Several clinical reports describe exacerbations of psychotic 
symptoms either on treatment with aripiprazole or during add-
on therapy with aripiprazole to different antipsychotic;72,73 the 
hypothesis being that dopamine agonism by aripiprazole 
during a hypodopaminergic state occurring with concomi-
tantly prescribed antipsychotics may lead to exacerbation of 
positive psychotic symptoms.72,74–79 Another rarely reported 
but important adverse event is drug-induced mania. Until 
now, very few cases have been described, but the potential 
ability of aripiprazole to precipitate manic episodes is a 
noteworthy phenomenon that has been described in schizoaf-
fective disorder,80 in schizophrenia,81 in obsessive-compulsive 
disorder,82 and generalized anxiety disorder.83 Although manic 
reactions seem to be marginal with respect to frequency of 
occurrence, they might have a biological plausibility and 
warrant clinical precautions.
Suicidality
To our knowledge, there are three published reports of 
increased suicidality after initiation of aripiprazole (one in 
“psychosis”,84 one in depression,85 and one article published 
in Dutch, with no English abstract available86).
Aripiprazole monotherapy  
in treatment-resistant schizophrenia
A multicenter, double-blind, randomized study compared the 
efficacy and safety of aripiprazole with that of perphenazine 
in 300 patients with treatment-resistant schizophrenia. 
  Treatment resistance was confirmed by 4–6 weeks of open-
label treatment with either olanzapine 10–20 mg/day or ris-
peridone 2–8 mg/day. Insufficient response was noted when 
improvements in the Positive and Negative Syndrome Scale 
(PANSS) total score were under 20% or the Clinical Global 
Impressions-Severity of Illness score was $4. Treatment-
resistant patients were eligible to enter a 6-week, double-blind 
treatment phase receiving either aripiprazole 15–30 mg/day 
or perphenazine 8–64 mg/day. Although both drug treat-
ments resulted in clinically relevant improvements in total 
PANSS scores (27% of patients treated with aripiprazole and 
25% of patients treated with perphenazine were reported 
as being responders) and in quality of life (36% of patients 
treated with aripiprazole versus 21% of patients treated 
with perphenazine), patients on aripiprazole exhibited fewer 
extrapyramidal symptoms and significantly less elevated 
prolactin levels.37 Some of the findings and conclusions of 
this industry-sponsored study have been criticized, including 
relatively more patients on aripiprazole than on perphenazine 
discontinuing the trial for reasons related to adverse effects.87 
A single case report describes complete symptomatic remis-
sion in a young patient with treatment-resistant schizophrenia 
during the course of a first psychotic episode on treatment 
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with high-dose aripiprazole (75 mg/day) without occurrence 
of adverse events.88 In summary, the evidence for aripiprazole 
monotherapy is currently based on one RCT with at least 
somewhat disputed data interpretation.
Aripiprazole as an alternative  
to clozapine
For the various reasons described above, many patients dis-
continue treatment with clozapine. There is a dearth of studies 
dealing with the dilemma of discontinuing and switching 
from clozapine in treatment-refractory schizophrenia. Two 
articles, including four cases, present precisely the results 
of switching from clozapine to aripiprazole, one due to lack 
of satisfactory response, the other three due to treatment 
intolerance because of neutropenia. The authors describe 
safe switches and clinically relevant effects with respect to 
symptom reduction and functioning.89,90 No broad conclu-
sions can be drawn from these case series.
Aripiprazole and clozapine
Although combination of clozapine with another antipsy-
chotic in patients having an unsatisfactory response is com-
mon in real-world settings, evidence-based strategies for 
combination therapy in clozapine-refractory schizophrenia 
are sparse. In recent years, efforts have been made to ascer-
tain the evidence of such case report-based strategies. A few 
RCT have focused on the efficacy of combinations of clo-
zapine with risperidone, haloperidol, amisulpride, sulpiride, 
and aripiprazole.21 Combining clozapine, a multireceptor 
drug with low affinity for the dopamine D2 receptor, and 
an antipsychotic with antidopaminergic properties follows 
a comprehensible neurobiological rationale regarding the 
pharmacodynamics of complementary receptor profiles. 
Pharmacokinetic interactions between clozapine and arip-
iprazole, such as effects on plasma levels, are not probable, 
given that aripiprazole and clozapine are metabolized by 
different cytochrome P450 (CYP) isoforms, ie, CYP3A4 
and CYP2D6 for aripiprazole, and CYP1A2 and to a lesser 
extent CYP2D6 for clozapine.91,92
Starting off with promising case reports53,93–99 and prospec-
tive or retrospective clinical observations,100–104 a small number 
of RCT were initiated to analyze the combination of clozapine 
and aripiprazole in treatment-resistant schizophrenia.105–108 
Most of the open-label and case studies as well as case reports 
show positive effects of this combination on overall psychopa-
thology53,93–95,99,101–104,109 and on negative symptoms.96,97,99,102,103 
Several reports describe the possibility of dose reduction for 
clozapine in combination with aripiprazole, a strategy that 
might help so-called treatment-intolerant patients.93,98,101,102 
Indeed, a review of 94 patients in 11 publications reports a 
clozapine dose reduction from 476.7 mg/day to 425 mg/day 
alongside an improvement in psychopathology, and a reduc-
tion in clozapine-related side effects with mean aripiprazole 
add-on therapy of 20.5 mg/day.110
To our knowledge, four RCT of aripiprazole in clozapine-
refractory patients with schizophrenia have been published 
(see Table 1),105–108 three of which were double-blind and 
placebo-controlled,105,106,108 one comparing aripiprazole with 
haloperidol using blinded raters.107 These RCT together 
included a total of approximately 400 patients. The trial by 
Fleischhacker et al investigated metabolic parameters as 
primary outcome variables, but outcome data on psychopa-
thology are also reported.106 The findings of these RCT with 
respect to changes in psychopathology seem less optimistic 
than those of the case reports and open-label trials. Two tri-
als report no benefits from aripiprazole in combination with 
clozapine compared with placebo106 or with haloperidol.107 
Improvements in negative symptoms were reported by Chang 
et al only after secondary analysis105 and by Muscatello et al 
only for alogia108 compared with the several promising non-
RCT reports mentioned above.
However, it should be noted that most RCT have included 
patients on stable mean clozapine doses at the lower end of the 
efficacy range (310.7 ± 73.1 mg/day,108 383 ± 158.2 mg/day,106 
304 ± 104.8 mg/day,105 421 ± 142 mg/day107), raising the 
question of whether patient symptoms were really refrac-
tory to treatment or if they were not treated at high enough 
doses because of intolerance. Furthermore, it is gener-
ally recommended to assess the efficacy of clozapine in 
treatment-resistant patients after a minimum of 3–6 months 
because delayed improvement is possible.111,112 However, 
RCT have used different inclusion criteria, thereby limiting 
comparability. For example, in the study by Muscatello et al, 
patients had to be on clozapine treatment for at least one year, 
but on a stable dose for a minimum of only one month,108 
Fleischhacker et al included patients who had been on a 
stable clozapine dose for a minimum of 3 months,106 Chang 
et al reported on a minimum treatment of one year with at 
least 2 months at a stable clozapine dose $ 400 mg,105 and, 
finally, Barbui et al included patients on stable clozapine 
doses for at least 6 months.107
The strongest beneficial effects of adding aripiprazole 
to clozapine that runs through the findings of the RCT, case 
reports, and open-label studies combined are better   metabolic 
outcomes and indicators of the possibility for   reducing the 
clozapine dose. However, other side effects, such as akath-
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isia, are repeatedly reported. Also, none of the studies report 
longer-term outcomes. In the light of the sobering results 
of the CATIE and CUtLASS (Cost Utility of the Latest 
  Antipsychotic Drugs in Schizophrenia Studies) trials.14,113 
Regarding the presumed superiority of second-generation 
antipsychotics when effectiveness instead of mere efficacy 
is assessed as the primary outcome parameter, it is notewor-
thy that most studies have assessed clinical efficacy but not 
effectiveness (ie, discontinuation rates).
Aripiprazole and other psychotropics
Other strategies have to be sought for patients who do not 
respond adequately to clozapine or its augmentation, or who 
are clozapine-intolerant. High-level evidence for specific 
augmentation strategies combining clozapine with other 
antipsychotics is still rather scant, and even moreso for com-
binations of antipsychotics other than clozapine. However, in 
the absence of alternatives, polypharmacy is a common strat-
egy in clinical practice, and encouraged by meta-analytical 
data favoring antipsychotic combinations over monotherapy 
in some clinical situations, such as combinations including 
clozapine, a trial duration of more than ten weeks, and parallel 
initiation of antipsychotic combinations and combinations of 
first-generation and second-generation antipsychotics.20
Combining aripiprazole with another antipsychotic seems 
to be worthy of further investigation from a pharmacological 
point of view, but relevant studies are almost nonexistent. 
A retrospective case series of combinations of aripiprazole 
with a wide range of other psychotropics in treatment-
resistant patients, including six patients with schizophrenia, 
reported moderate to adequate improvement and good 
tolerability. Combinations included risperidone long-acting 
injection and haloperidol, clozapine, ziprasidone, quetiapine 
and olanzapine, and quetiapine and risperidone, all of which 
were augmented with aripiprazole.114
In a multicenter RCT of 323 patients with schizophrenia 
or schizoaffective disorder with a chronic course, but not 
explicitly termed treatment-resistant, adjunctive administration 
of aripiprazole 2–15 mg/day with risperidone 4–8 mg/day or 
quetiapine 400–800 mg/day revealed no significant improve-
ment in psychiatric symptoms assessed by PANSS, but was 
broadly well tolerated.115 No further conclusions can be drawn 
regarding aripiprazole combined with other psychotropics for 
treatment-resistant schizophrenia from the available data.
Conclusion
From the pharmacological and clinical points of view, 
  aripiprazole seems worthy of further investigation for 
  clozapine-resistant and clozapine-intolerant patients. 
The evidence for aripiprazole monotherapy and for the 
combination of aripiprazole with psychotropics other than 
clozapine is scant, and no recommendations can be drawn 
from the currently available data. More effort has been made 
in describing combinations of aripiprazole and clozapine. 
While open-label and case studies show improvement in 
overall psychopathology and in negative symptoms, results of 
RCT are inconclusive regarding effects on psychopathology. 
Given the potential of most antipsychotics to induce del-
eterious metabolic effects, the repeated finding of a lesser 
metabolic impact of aripiprazole is noteworthy. This, as well 
as the potential effects concerning dosage reduction, might 
be of particular value in patients treated with   clozapine. 
However, other side effects, such as agitation and akathisia, 
have been repeatedly reported, and others, such as exacer-
bation of psychosis, seem rare but severe. In summary, in 
this specific population   unresponsive to   previous treatment, 
a combination of clozapine with aripiprazole, as well as 
other augmentation strategies for clozapine, seem worthy 
of further exploration. However, given the lack of clearcut 
evidence for an advantage of antipsychotic polypharmacy 
in general, no confident recommendations can be made 
and careful clinical appraisal of the risk-benefit ratio of all 
options is warranted.
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